Kyverna Therapeutics (KYTX) Current Leases (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Current Leases data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 42.69% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 42.69% YoY), and the FY2025 full-year result was $307000.0, down 90.29% from the prior year.
• Current Leases for Q1 2026 stood at $1.8 million, up from $307000.0 in the prior quarter.
• Across five years, Current Leases topped out at $3.3 million in Q2 2025 and bottomed at $190000.0 in Q3 2025.
• The 4-year median for Current Leases is $2.8 million (2024), against an average of $2.2 million.
• The widest annual swing landed in 2024, when Current Leases surged 60.95%; it then plunged 93.67% in 2025.
• A 4-year view of Current Leases shows it stood at $2.0 million in 2023, then soared by 60.95% to $3.2 million in 2024, then sank by 90.29% to $307000.0 in 2025, then soared by 474.59% to $1.8 million in 2026.
• The last three Current Leases figures came in at $1.8 million (Q1 2026), $307000.0 (Q4 2025), and $190000.0 (Q3 2025), per Business Quant data.

Peer Comparison